FDA draft guidance lets one licence cover patient-specific gene-editing therapies

The FDA has set out how one licence could cover gene-editing treatments made for individual patients. On 27 October it published draft guidance, *Individualized Human Genome Editing Products: Considerations for BLA Submission and Postapproval Management*, as part of a joint FDA and CMS announcement that also widens CMS's Cell and Gene Therapy Access Model beyond sickle cell disease.

What the guidance does

Without it, each patient-specific version of a gene-editing product would in effect need its own approval. CBER's Andrew Byrnes, director of the Division of Gene Therapy 1, called the one-BLA-per-variant approach "infeasible", according to RAPS. The draft lets sponsors put several variants into one BLA and add new ones after approval.

Get The Biotech Brief every TuesdayThree-minute read. Free. One-click unsubscribe.

The core idea is the Individualized Feature Space (IFS): limits, agreed in advance, on how far the editing components can vary from one patient's version to the next. If a new variant falls inside those limits and lab assays show adequate safety and activity, it can be added through a streamlined review. That review relies on the original approval trials plus in vitro data, not a new clinical trial.

The scope is narrow. It covers products meant to prevent, treat or cure a monogenic disease caused by known pathogenic variants, where every version is designed to achieve the same editing outcome. The draft also covers manufacturing and control strategy, potency and safety testing (including unintended genetic changes), process validation, and naming and labelling. Comments are open for 30 days after Federal Register publication, under docket FDA-2026-D-11783.

"For patients with rare genetic diseases, a one size fits all approach to treatment simply does not work" Kyle Diamantas, J.D., Acting Commissioner of Food and Drugs

The access side

CMS's Cell and Gene Therapy Access Model negotiates outcomes-based deals with manufacturers on behalf of state Medicaid programmes. It has so far covered sickle cell disease. CMS will invite manufacturers of therapies for other conditions to apply, through a request for applications due in the coming months, which will also accept therapies that are already approved. CMS says its first evaluation found joint negotiation reduced states' administrative work and strengthened their bargaining position.

Why CMC teams should care

PharmTech's analysis argues that the IFS moves much of the evidence for new variants from clinical data to analytical and process data. On-target and off-target editing assays, and proof that the platform process stays consistent as patient-specific parts change, become central to a filing. Where to draw the IFS boundaries becomes partly a CMC call: too narrow and a licence serves few patients, too broad and it is hard to support with data.

RAPS notes the draft builds on a run of earlier guidance, including a February 2026 draft on the plausible mechanism framework for individualised therapies and an April 2026 draft on sequencing-based safety assessment. It is still a draft, but the direction is now clear.

What it means for hiring

If this approach is finalised, the hardest gene-editing roles may shift from running trials to building the analytical case. We'd expect strong demand for CMC, analytical development and off-target assay leaders with genome editing experience.
Regulatory affairs leaders who can negotiate an IFS with CBER early in development become more valuable. Small gene-editing companies that have relied on consultants may want this capability in-house.
The CMS model expansion makes market access and pricing strategy an earlier conversation for cell and gene therapy companies, including those still in the clinic.

Share Ask Jordan about this →